A BILL 
To amend title XIX of the Social Security Act to establish 
a demonstration project to improve outpatient clinical 
care for individuals with sickle cell disease. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Sickle Cell Disease 
4
Comprehensive Care Act’’. 
5
22:39 Dec 17, 2021
H6216
2 
•HR 6216 IH
SEC. 2. MEDICAID DEMONSTRATION PROJECT TO IMPROVE 
1
OUTPATIENT CLINICAL CARE FOR INDIVID-
2
UALS WITH SICKLE CELL DISEASE. 
3
Section 1903 of the Social Security Act (42 U.S.C. 
4
1396b) is amended by adding at the end the following new 
5
subsection: 
6
‘‘(cc) DEMONSTRATION PROJECT TO IMPROVE OUT-
7
PATIENT CLINICAL CARE FOR INDIVIDUALS WITH SICKLE 
8
CELL DISEASE.— 
9
‘‘(1) IN
GENERAL.—Notwithstanding section 
10
1902(a)(1) (relating to statewideness), section 
11
1902(a)(10)(B) (relating to comparability), and any 
12
other provision of this title for which the Secretary 
13
determines it is necessary to waive in order to imple-
14
ment this subsection, not later than the date that is 
15
1 year after the date of the enactment of this sub-
16
section, the Secretary shall, in consultation, as ap-
17
propriate, with the Administrator of the Health Re-
18
sources and Services Administration, the Director of 
19
the Agency for Healthcare Research and Quality, 
20
and the Deputy Assistant Secretary for Minority 
21
Health, conduct a 5 year demonstration project (re-
22
ferred to in this subsection as the ‘demonstration 
23
project’) for the purpose described in paragraph (2) 
24
under which the Secretary shall— 
25
22:39 Dec 17, 2021
H6216
3 
•HR 6216 IH
‘‘(A) for the first 18-month period of such 
1
project, award planning grants described in 
2
paragraph (3); and 
3
‘‘(B) for the remaining 42-month period of 
4
such project, provide payments to each State 
5
selected under paragraph (4) in accordance 
6
with paragraph (5). 
7
‘‘(2) PURPOSE.—The purpose described in this 
8
paragraph is for each State that participates in the 
9
demonstration project to improve access to high- 
10
quality outpatient care for individuals receiving serv-
11
ices under the State plan (or waiver of such plan) 
12
who are living with sickle cell disease (with a focus 
13
on, but not limited to, young adults and pregnant 
14
women), to improve clinical, mental health, ancillary, 
15
and support services, and to reduce overall and long- 
16
term costs, as appropriate, to the State associated 
17
with treating individuals with sickle cell disease 
18
under the State plan (or waiver of such plan) 
19
through the following activities: 
20
‘‘(A) Supporting the creation or augmenta-
21
tion of multi-disciplinary care teams that in-
22
clude the physicians needed to adequately treat 
23
an individual for sickle cell disease and its com-
24
plications, as determined by the Secretary in 
25
22:39 Dec 17, 2021
H6216
4 
•HR 6216 IH
consultation with the appropriate stakeholders, 
1
including organizations representing sickle cell 
2
disease patients, hematologists, and other spe-
3
cialists in sickle cell disease care and treatment. 
4
‘‘(B) Conducting an assessment of the bar-
5
riers to care experienced by individuals with 
6
sickle cell disease enrolled under the State plan 
7
(or waiver of such plan), taking into account so-
8
cial, demographic, and economic factors, geog-
9
raphy, provider shortages, and other issues con-
10
tributing to health inequities, as determined by 
11
the Secretary in consultation with relevant 
12
stakeholders, 
including 
organizations 
rep-
13
resenting sickle cell disease patients, hema-
14
tologists, and other specialists in sickle cell dis-
15
ease care and treatment. 
16
‘‘(C) Identifying best practices for improv-
17
ing health equity for individuals with sickle cell 
18
disease enrolled under the State plan (or waiver 
19
of such plan) which take into account the re-
20
sults of the assessment described in subpara-
21
graph (B), and communicating such best prac-
22
tices through the provision of education, train-
23
ing, and technical assistance to providers par-
24
ticipating under the State plan (or waiver of 
25
22:39 Dec 17, 2021
H6216
5 
•HR 6216 IH
such plan), including to care teams described in 
1
subparagraph (A). 
2
‘‘(D) Expanding expertise of providers par-
3
ticipating under the State plan (or waiver of 
4
such plan) on care for sickle cell disease by dis-
5
seminating clinical practice guidelines for sickle 
6
cell disease and providing education, training, 
7
and technical assistance with respect to such 
8
guidelines to such providers. 
9
‘‘(E) Ensuring that sickle cell disease pa-
10
tients enrolled under the State plan (or waiver 
11
of such plan) are getting primary and preven-
12
tive services in an appropriate outpatient set-
13
ting or through telehealth services, as appro-
14
priate, including by providing additional reim-
15
bursement for care coordinators, community 
16
health workers, and other non-traditional serv-
17
ice providers. 
18
‘‘(F) Developing an individualized, com-
19
prehensive, patient-centered care plan for indi-
20
viduals with sickle cell disease that accommo-
21
dates patient preferences in a culturally and lin-
22
guistically appropriate manner. 
23
‘‘(G) Ensuring that sickle cell disease pa-
24
tients enrolled under the State plan (or waiver 
25
22:39 Dec 17, 2021
H6216
6 
•HR 6216 IH
of such plan) are provided with coordination of, 
1
and access to, the following services, as deter-
2
mined to be clinically appropriate: 
3
‘‘(i) Treatments and medications, in-
4
cluding chronic and exchange transfusions 
5
and disease-modifying medications. 
6
‘‘(ii) Appropriate diagnostic testing 
7
such as magnetic resonance imaging. 
8
‘‘(iii) Pain management treatment 
9
and palliative care. 
10
‘‘(iv) Services provided by subspecial-
11
ists such as obstetricians and gyne-
12
cologists, reproductive health specialists, 
13
urologists, ophthalmologists, neurologists, 
14
nephrologists, psychologists, orthopedists, 
15
cardiologists, and pulmonologists. 
16
‘‘(v) Supportive clinical services, in-
17
cluding vision and dental care. 
18
‘‘(vi) Mental health services and sub-
19
stance use disorder treatment. 
20
‘‘(vii) Transportation to medical serv-
21
ices and social support services and refer-
22
rals to community based organizations. 
23
‘‘(viii) Any other therapies approved 
24
by the Food and Drug Administration for 
25
22:39 Dec 17, 2021
H6216
7 
•HR 6216 IH
the treatment of sickle cell disease or its 
1
complications. 
2
‘‘(ix) Any other services deemed ap-
3
propriate for the treatment of sickle cell 
4
disease or its complications by the State. 
5
‘‘(H) Providing other services or taking 
6
other actions deemed necessary to improve 
7
treatment of sickle cell disease under the State 
8
plan (or waiver of such plan), as determined by 
9
the Secretary in coordination with relevant 
10
stakeholders, 
including 
organizations 
rep-
11
resenting sickle cell disease patients, hema-
12
tologists, and other specialists in sickle cell dis-
13
ease care and treatment. 
14
‘‘(3) PLANNING GRANTS.— 
15
‘‘(A) IN
GENERAL.—The Secretary shall 
16
award planning grants to at least 10 States se-
17
lected in accordance with subparagraph (B) for 
18
purposes of preparing an application described 
19
in paragraph (4)(C) and carrying out the activi-
20
ties described in subparagraph (C). 
21
‘‘(B) SELECTION.—In selecting States for 
22
purposes of this paragraph, the Secretary 
23
shall— 
24
22:39 Dec 17, 2021
H6216
8 
•HR 6216 IH
‘‘(i) select States that have a State 
1
plan approved under this title; 
2
‘‘(ii) give priority to States that have 
3
participated in the sickle cell disease sur-
4
veillance data collection program of the 
5
Centers for Disease Control and Preven-
6
tion or precursors to such program; and 
7
‘‘(iii) select States in a manner to rec-
8
ognize States with a higher prevalence of 
9
sickle cell disease patients that could be 
10
reached 
through 
this 
demonstration 
11
project. 
12
‘‘(C) ACTIVITIES
DESCRIBED.—Activities 
13
described in this subparagraph are, with respect 
14
to a State, each of the following: 
15
‘‘(i) Activities that support an assess-
16
ment of the treatment needs and gaps in 
17
care in the State for individuals with sickle 
18
cell disease in order to improve the net-
19
work of providers that treat this popu-
20
lation, including the following: 
21
‘‘(I) An estimate of the number 
22
of individuals enrolled under the State 
23
plan (or a waiver of such plan) who 
24
have sickle cell disease. 
25
22:39 Dec 17, 2021
H6216
9 
•HR 6216 IH
‘‘(II) Information on the capacity 
1
of providers with the knowledge need-
2
ed to treat sickle cell disease and the 
3
complications of sickle cell disease, in-
4
cluding information on providers who 
5
provide such services and their par-
6
ticipation under the State plan (or 
7
waiver of such plan). 
8
‘‘(III) Information on the gaps in 
9
care for treatment of individuals with 
10
sickle cell disease under the State 
11
plan (or waiver of such plan), includ-
12
ing information based on the assess-
13
ments described in subclauses (I) and 
14
(II). 
15
‘‘(ii) Activities that, taking into ac-
16
count the results of the assessment de-
17
scribed in clause (i), support the develop-
18
ment of State infrastructure to recruit pro-
19
spective providers and provide training and 
20
technical assistance to providers with re-
21
spect to treatment of sickle cell disease 
22
under the State plan (or a waiver of such 
23
plan). 
24
22:39 Dec 17, 2021
H6216
10 
•HR 6216 IH
‘‘(D) FUNDING.—For the purpose of mak-
1
ing grants under this paragraph, there is appro-
2
priated to the Secretary, out of any funds in 
3
the 
Treasury 
not 
otherwise 
appropriated, 
4
$25,000,000, to remain available until ex-
5
pended. 
6
‘‘(4) POST-PLANNING GRANT STATES.— 
7
‘‘(A) IN GENERAL.—The Secretary shall, 
8
with respect to the remaining 42-month period 
9
of the demonstration project conducted under 
10
paragraph (1), select up to 10, but not less 
11
than 5 States in accordance with subparagraph 
12
(B) for purposes of carrying out the activities 
13
described in paragraph (2) and receiving pay-
14
ments in accordance with paragraph (5). The 
15
Secretary may select all States that received a 
16
planning grant in paragraph (3). 
17
‘‘(B) SELECTION.—In selecting States for 
18
purposes of this paragraph, the Secretary 
19
shall— 
20
‘‘(i) select States that received a plan-
21
ning grant under paragraph (3) and have 
22
successfully completed the activities de-
23
scribed in subparagraph (C) of such para-
24
graph; 
25
22:39 Dec 17, 2021
H6216
11 
•HR 6216 IH
‘‘(ii) select States that submit to the 
1
Secretary an application in accordance 
2
with the requirements in subparagraph 
3
(C); and 
4
‘‘(iii) select States in a manner con-
5
sistent with reaching as many sickle cell 
6
disease patients as possible through the 
7
demonstration project. 
8
‘‘(C) APPLICATIONS.— 
9
‘‘(i) IN GENERAL.—A State seeking to 
10
be selected for purposes of this paragraph 
11
shall submit to the Secretary, at such time 
12
and in such form and manner as the Sec-
13
retary requires, an application that in-
14
cludes such information as the Secretary 
15
may require, in addition to the following: 
16
‘‘(I) A proposed process for car-
17
rying out the activities described in 
18
paragraph (2). 
19
‘‘(II) A review of reimbursement 
20
methodologies and other policies re-
21
lated to sickle cell disease treatment 
22
under the State plan (or waiver of 
23
such plan) that may create barriers to 
24
22:39 Dec 17, 2021
H6216
12 
•HR 6216 IH
increasing the number of providers de-
1
livering such services. 
2
‘‘(III) The development of a plan, 
3
taking into account activities carried 
4
out under paragraph (3)(C)(ii), that 
5
will result in long-term and sustain-
6
able provider networks under the 
7
State plan (or waiver of such plan) for 
8
sickle cell disease. 
9
‘‘(IV) A proposed process for re-
10
porting 
the 
information 
required 
11
under paragraph (6)(A). 
12
‘‘(V) The expected financial im-
13
pact of the demonstration project 
14
under this subsection on the State. 
15
‘‘(VI) A description of all funding 
16
sources available to the State to pro-
17
vide treatment for sickle cell disease 
18
under the State plan (or waiver of 
19
such plan) in the State. 
20
‘‘(VII) A preliminary plan for 
21
how the State will sustain any in-
22
crease in the capacity of providers to 
23
deliver treatment for sickle cell dis-
24
ease and the complications of sickle 
25
22:39 Dec 17, 2021
H6216
13 
•HR 6216 IH
cell disease resulting from the dem-
1
onstration project under this sub-
2
section after the termination of such 
3
demonstration project. 
4
‘‘(VIII) A description of how the 
5
State will coordinate the goals of the 
6
demonstration project with any waiver 
7
granted (or submitted by the State 
8
and pending) pursuant to section 
9
1115 for the delivery of services to 
10
treat sickle cell disease under the 
11
State plan, as applicable. 
12
‘‘(ii) CONSULTATION.—In completing 
13
an application under clause (i), a State 
14
shall consult with relevant stakeholders, in-
15
cluding Medicaid managed care plans, he-
16
matologists and other sickle cell disease 
17
specialists, and Medicaid beneficiaries and 
18
sickle cell disease advocates, and include in 
19
such application a description of such con-
20
sultation. 
21
‘‘(5) PAYMENTS.— 
22
‘‘(A) ENHANCED FMAP FOR SICKLE CELL 
23
DISEASE
TREATMENT.—Notwithstanding sec-
24
tion 1905(b), for each quarter occurring during 
25
22:39 Dec 17, 2021
H6216
14 
•HR 6216 IH
the period for which the demonstration project 
1
is conducted (after the first 18 months of such 
2
period), the Federal medical assistance percent-
3
age for each State selected under paragraph (4) 
4
with respect to amounts expended by the State 
5
for medical assistance for medically necessary 
6
services to treat sickle cell disease shall be equal 
7
to 100 percent. 
8
‘‘(B) CASE
MANAGEMENT
SERVICES
FOR 
9
SICKLE CELL DISEASE PATIENTS.— 
10
‘‘(i) IN GENERAL.—During the period 
11
for which the demonstration project is con-
12
ducted (after the first 18 months of such 
13
period), a State selected under paragraph 
14
(4) may provide a multi-disciplinary care 
15
team described in paragraph (2)(A) with 
16
payments for the provision of case manage-
17
ment and care coordination services to an 
18
individual with sickle cell disease who is el-
19
igible under the State plan (or waiver of 
20
such plan). Payments made to such a team 
21
shall be treated as medical assistance for 
22
purposes of section 1903(a) except that the 
23
Federal medical assistance percentage ap-
24
22:39 Dec 17, 2021
H6216
15 
•HR 6216 IH
plicable to such payments shall be equal to 
1
100 percent. 
2
‘‘(ii) METHODOLOGY.—A State that 
3
elects to make case management and care 
4
coordination payments to a multi-discipli-
5
nary care team under this subparagraph 
6
shall specify in a State’s application under 
7
paragraph (4) the methodology the State 
8
will use for determining payment for the 
9
provision of such services. Such method-
10
ology shall not be limited to a per-member- 
11
per-month basis and may provide (as pro-
12
posed by the State and subject to approval 
13
by the Secretary) for alternate models of 
14
payment. 
15
‘‘(6) REPORTS.— 
16
‘‘(A) STATE REPORTS.—A State receiving 
17
payments under paragraph (5) shall, for the pe-
18
riod of the demonstration project under this 
19
subsection, submit to the Secretary a quarterly 
20
report, with respect to expenditures for treat-
21
ment of sickle cell disease and complications of 
22
sickle cell disease for which payment is made to 
23
the State under this subsection, on the fol-
24
lowing: 
25
22:39 Dec 17, 2021
H6216
16 
•HR 6216 IH
‘‘(i) The specific activities with re-
1
spect to which payment under this sub-
2
section was provided. 
3
‘‘(ii) The number of individuals en-
4
rolled under the State plan (or a waiver of 
5
such plan) who received treatment for sick-
6
le cell disease or complications related to 
7
sickle cell disease under the demonstration 
8
project compared to the estimated number 
9
of such individuals who would have other-
10
wise received such services in the absence 
11
of such demonstration project. 
12
‘‘(iii) The number of individuals en-
13
rolled under the State plan (or waiver of 
14
such plan) who received treatment for sick-
15
le cell disease or complications related to 
16
sickle cell disease under the demonstration 
17
project who utilized the services beyond 
18
clinical sickle cell disease services, includ-
19
ing mental health, ancillary and support 
20
services and the impact on their health 
21
outcomes, including emergency department 
22
visits and inpatient hospital stays. 
23
‘‘(iv) The reductions in inpatient days, 
24
reductions in emergency department visits, 
25
22:39 Dec 17, 2021
H6216
17 
•HR 6216 IH
and reductions in the total cost of care 
1
compared to these metrics before the dem-
2
onstration project was implemented. 
3
‘‘(v) Other matters as determined by 
4
the Secretary. 
5
‘‘(B) CMS REPORTS.— 
6
‘‘(i) INITIAL REPORT.—Not later than 
7
18 months after the date of enactment of 
8
this subsection, the Administrator of the 
9
Centers for Medicare & Medicaid Services, 
10
in consultation with the Administrator of 
11
the Health Resources and Services Admin-
12
istration, shall submit to Congress an ini-
13
tial report on— 
14
‘‘(I) the States awarded planning 
15
grants under paragraph (3); 
16
‘‘(II) the criteria used in such se-
17
lection; and 
18
‘‘(III) the activities carried out 
19
by such States under such planning 
20
grants. 
21
‘‘(ii) INTERIM
REPORT.—Not later 
22
than 3 years after the date of enactment 
23
of this subsection, the Administrator of the 
24
Centers for Medicare & Medicaid Services 
25
22:39 Dec 17, 2021
H6216
18 
•HR 6216 IH
shall, submit to Congress an interim re-
1
port— 
2
‘‘(I) on activities carried out 
3
under 
the 
demonstration 
project 
4
under this subsection; 
5
‘‘(II) on the extent to which 
6
States selected under paragraph (4) 
7
have achieved the activities submitted 
8
in their applications under subpara-
9
graph (C) of such paragraph; 
10
‘‘(III) with a description of the 
11
strengths and limitations of such dem-
12
onstration project; and 
13
‘‘(IV) with a plan for the sustain-
14
ability of such project. 
15
‘‘(iii) FINAL REPORT.—Not later than 
16
1 year following the implementation of the 
17
demonstration project, the Secretary shall 
18
submit to Congress and make public a 
19
final report— 
20
‘‘(I) providing updates on the 
21
matters reported in the interim report 
22
under clause (ii); 
23
‘‘(II) including a description of 
24
any changes made with respect to the 
25
22:39 Dec 17, 2021
H6216
19 
•HR 6216 IH
demonstration project under this sub-
1
section after the submission of such 
2
interim report; and 
3
‘‘(III) 
evaluating 
such 
dem-
4
onstration project. 
5
‘‘(C) 
REPORT
ON
EXPERIENCES
OF 
6
STATES.—Not later than 3 years after the date 
7
of the enactment of this subsection, the Admin-
8
istrator of the Centers for Medicare & Medicaid 
9
Services, in consultation with the Director of 
10
the Agency for Healthcare Research and Qual-
11
ity, shall submit to Congress a summary on the 
12
experiences of States awarded planning grants 
13
under paragraph (3) and States selected under 
14
paragraph (4). 
15
‘‘(7) DATA SHARING AND BEST PRACTICES.— 
16
During the period of the demonstration project 
17
under this subsection, the Secretary shall, in collabo-
18
ration with States selected under paragraph (4), fa-
19
cilitate information sharing and the exchange of 
20
identified best practices between— 
21
‘‘(A) provider who treat sickle cell disease; 
22
and 
23
‘‘(B) States selected under paragraph (4) 
24
and States that were not so selected. 
25
22:39 Dec 17, 2021
H6216
20 
•HR 6216 IH
‘‘(8) CMS FUNDING.—There is appropriated, 
1
out of any funds in the Treasury not otherwise ap-
2
propriated, $50,000,000 to the Centers for Medicare 
3
& Medicaid Services for purposes of implementing 
4
this subsection, including completing the reports to 
5
Congress required under this Act. Such amount 
6
shall remain available until expended.’’. 
7
Æ 
22:39 Dec 17, 2021
H6216
